Dr Malik Janjua FRACP
Gastroenterologist / Inflammatory Bowel Disease Specialist, Fiona Stanley Hospital
Dr Malik Janjua is an adult gastroenterologist and hepatologist who has received training at numerous institutions, both locally and overseas.
He completed his basic physician training and subsequently advanced training in gastroenterology and hepatology in Perth. Following this, he completed two clinical and research fellowships in inflammatory bowel disease, one at Royal Perth Hospital and the other at the Royal Devon and Exeter Hospital, United Kingdom.
He has a special interest in the diagnosis and management of inflammatory bowel disease, the management of Coeliac disease and colorectal cancer screening. He has accreditation in colonoscopy, gastroscopy and capsule endoscopy from the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy. He is a member of the Royal Australasian College of Physicians and the Gastroenterological Society of Australia.
Publications
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, Goodhand JR; PANTS consortium. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? Aliment Pharmacol Ther. 2022 Sep;56(5):783-793. doi: 10.1111/apt.17089. Epub 2022 Jun 29. PMID: 35768996; PMCID: PMC9540440.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. PMID: 35296643; PMCID: PMC8927425.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28. PMID: 35902214.
Jayabalan D, Huang Y, Calzadilla-Bertot L, Janjua M, de Boer B, Joseph J, Cheng W, Hazeldine S, Smith BW, MacQuillan GC, Wallace MC, Garas G, Adams LA, Jeffrey GP. Predictors of survival in autoimmune liver disease overlap syndromes. World J Hepatol. 2024 Sep 27;16(9):1269-1277. doi: 10.4254/wjh.v16.i9.1269. PMID: 39351512; PMCID: PMC11438591.